The evolution of adjuvant endocrine therapy: Developments since St Gallen 2005

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 4-9

  Smith, Ian E ^a,b   Arnedos, Monica ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Adjuvant; Aromatase inhibitors; Endocrine therapy; Ovarian suppression; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DYSPAREUNIA; ENDOMETRIUM CARCINOMA; FRACTURE; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS CARCINOMA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM;

EID: 35648941581     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.001     Document Type: Article

References (37)

1. Schinzinger A. Ueber carcinoma mammae. Verh Dtsch Ges Chir 18 (1889) 28-29
2. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet ii (1896) 104-107
3. Cole MP, Namer M, Lalanne CM, editors. A clinical trial of an artificial menopause in carcinoma of the breast. Hormones and breast cancer. 55th ed. Paris: INSERM; 1975. p. 143.
4. Early Breast Cancer Trialists' Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
5. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1 8319 (1983) 257-261
6. Baum M., Budzar A.U., Cuzick, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
7. BIG 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
8. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 9 (2001) 684-690
9. Buzdar A.U., and Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12 3 Pt 2 (2006) 1037s-1048s
10. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007) 486-492
11. Arpino G., Weiss H., Lee A.V., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97 17 (2005) 1254-1261
12. Dowsett M., Cuzick J., Wale C., Howell A., Houghton J., and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 30 (2005) 7512-7517
13. Dowsett, et al. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100 Suppl 1 (2006) 48 [abstract]
14. Mauriac L, Keshaviah A, Debled M, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007 [Published ahead of print].
15. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 19 18 (2001) 3808-3816
16. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the immediate, preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomised trial. J Clin Oncol 23 22 (2005) 5108-5116
17. Duffy S., Jackson T.L., et al. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 21 2 (2006) 545-553
18. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
19. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 9561 (2007) 559-570
20. Goss P.E., Ingle J.N., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 17 (2005) 1262-1271
21. Jonat W., Gnant M., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 12 (2006) 991-996
22. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 22 (2005) 5138-5147
23. Jakesz R., Jonat W., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
24. Jakesz R., Gnant M., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG trial 8. Breast Cancer Res Treat 94 Suppl 1 (2005) 13 [abstract]
25. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 10 (1996) 2738-2746
26. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years tamoxifen therapy for early stage breast cancer. N Engl J Med 349 19 (2003) 1-10
27. Ingle J., Tu N.D., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99 3 (2006) 295-300
28. Jakesz R., Samonigg H., et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23 16S (2005) 527 [abstract]
29. Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24 16 (2006) 2444-2447
30. Kendall A., Dowsett M., Folkerd E., et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17 4 (2006) 584-587
31. Jonat W., Kaufmann, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopaussal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20 24 (2002) 4628-4635
32. Jakesz R., Hausmaninger H., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Research Association Study. J Clin Oncol 20 24 (2002) 4621-4627
33. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99 2 (2007) 167-170
34. Paik S., Shak S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
35. Van der van't Veer L., Dai J.H., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
36. Van de Vijver M.J., He Y.D., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 25 (2002) 1999-2009
37. Davidson N., O'Neill A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23 25 (2005) 5973-5982